The Clinical Research Of Thrombospondin-1as A Supplemental Diagnosis Of Prostate Cancer

[Abstract] Objective To use enzyme-linked immunosorbent assay (ELISA) for measuring serum thrombospondin-1(TSP-1) levels, and to analyze its diagnostic value for prostate cancer. Method To measure serum TSP-1levels in50patients with prostate cancer (22patients with organ-confined prostate cancer,28patients with non-organ-confined prostate cancer)、20patients with benign prostatic hyperplasia (BPH) and18healthy people by using human TSP-1ELISA kit. Results The average concentration of serum TSP-1was200.24+48.78ng/ml in prostate cancer group,281.46±53.38ng/ml in BPH group and323.41±56.45ng/ml in healthy people group, statistical analysis showed significant difference of serum level of TSP-1between groups (P<0.05). The average concentration of serum TSP-1was215.60±34.07ng/ml in organ-confined prostate cancer (including I stage and II stage) and188.18±48.92ng/ml in non-organ-confined prostate cancer (including III stage and IV stage), respectively (P=0.030). TSP-1level also correlated with Gleason score(r=-0.32, P=0.023). However, the relationship between TSP-1levels and lymph node metastasis was still unclear (P=0.189). The diagnostic sensitivity and specificity of TSP-1and prostate specific antigen (PSA) for prostate cancer were72%,90%and64%,70%, respectively (P<0.05). The area under the receiver operating characteristic curve (ROC) of TSP-1and PSA were0.8905and0.719, respectively (P=0.028). Conclusions The TSP-1is a relatively ideal candidate of predictor of prostate cancer. The serum TSP-1concentration can not only distinguish prostate cancer from BPH, but also correlate with tumor stage and Gleason grade.